LYMPHOID NEOPLASMS
Emil J. Freireich, MD, DSc
The University of Texas MD Anderson Cancer Center
Refined multidrug chemotherapy regimens that form the backbone of treatment today
    Emil J. Freireich, MD, is the Ruth Harriet Ainsworth Chair in the Department of Developmental Therapeutics at The University of Texas MD Anderson Cancer Center. His work and accomplishments include:
    • Collaborated with James Holland, MD, and Emil Frei III, MD, to develop combination chemotherapy and organize the first cooperative group
    • Developed the first “curative therapy” for metastatic cancer in childhood acute lymphoblastic leukemia: POMP—prednisone, oncovin, methotrexate, purinethol (6-MP)
    • First to perform leukocyte transfusion and to demonstrate engrafting of peripheral blood stem cells, providing allogeneic bone marrow grafts
    • Developed allogeneic platelet transfusion and treatment strategies for infectious complications
    • Patented the first continuous-flow blood cell separator, which is used in most pheresis centers
    • Continues to work in the Department of Leukemia, where he cares for patients with leukemia and supervises research protocols for treatment of this disease
    • In his joint appointment with the Department of Laboratory Medicine, collaborates on an important transfusion study
    • Obtained one of the first formal training program grants in medical oncology at MD Anderson, and serves on the Division of Cancer Medicine Committee for Medical Oncology Fellow Training
Program Information:
Nominate
Sponsor
News
Previous Inductees:
2013 | 2014
2015 | 2016
2017 | 2018
Connect: